Cytomegalovirus infection after liver transplantation

Liver Transplantation

Volumn 16, Issue SUPPL. 2, 2010, Pages

  Razonable, Raymund R ^a  

^a Department of Health Sciences Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

ANTIVIRAL THERAPY; ARTICLE; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; FEVER; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR;

EID: 78651400499     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22144     Document Type: Article

References (25)

1. Razonable R., Direct and indirect effects of cytomegalovirus: can we prevent them? Enferm Infect Microbiol Clin 2010; 28: 1-5.
2. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR., Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13: 1703-1709.
3. Razonable RR., Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008; 14: 4849-4860.
4. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35: 974-981. (Pubitemid 35178315)
5. Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, Boeckh M., Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 1390-1396. (Pubitemid 39507981)
6. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652. (Pubitemid 43948296)
7. Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GF, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2005; 4:CD003774.
8. Hodson EM, Craig JC, Strippoli GF, Webster AC., Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; 2:CD003774.
9. Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC., Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007; 2:CD005129.
10. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105-2115. (Pubitemid 40826968)
11. Strippoli GF, Hodson EM, Jones C, Craig JC., Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139-145.
12. Strippoli GF, Hodson EM, Jones CJ, Craig JC., Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2006; 1:CD005133.
13. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214-1222.
14. Humar A, Snydman D., Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S78-S86.
15. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
16. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461-1464. (Pubitemid 33108862)
17. Eid AJ, Razonable RR., New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965-981.
18. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG., A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8: 158-161.
19. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620. (Pubitemid 38523584)
20. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
21. Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205-1213.
22. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106-2113. (Pubitemid 47247057)
23. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR., Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010; 10: 157-161.
24. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR., Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22: 162-170.
25. Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5: 1065-1070. (Pubitemid 40571255)